# SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

URL: https://app.greenveil.ai/ingredients/ingredient_dtxsid_dtxsid6073994
Categories: cleaning, food, industrial, pharma
Identifier: DTXSID6073994

> SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE. EPA CPDat observed this chemical in 98 composition records across product categories including Laboratory supplies, Pet and animal care, Specialty occupational products. Assessed from 42 sources.

## Safety assessment

- Chemical concern: not yet assessed
- Rationale: EPA CPDat observed this chemical in 98 composition records across product categories including Laboratory supplies, Pet and animal care, Specialty occupational products.

## Regulatory status

- US: commercial use observed — EPA CPDat observed this chemical in 98 composition records across product categories including Laboratory supplies, Pet and animal care, Specialty occupational products.
- US: inactive ingredient database — Route: INTRA-ARTICULAR; Dosage form: INJECTION; Maximum daily exposure: 14 mg
- US: inactive ingredient database — Route: INTRA-ARTICULAR; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 13 mg
- US: inactive ingredient database — Route: INTRALESIONAL; Dosage form: INJECTION; Maximum daily exposure: 14 mg
- US: inactive ingredient database — Route: INTRALESIONAL; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 13 mg
- US: inactive ingredient database — Route: INTRAMUSCULAR; Dosage form: INJECTION; Maximum daily exposure: 120 mg
- US: inactive ingredient database — Route: INTRAMUSCULAR; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: 1.84 mg
- US: inactive ingredient database — Route: INTRAMUSCULAR; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: 15.55 mg
- US: inactive ingredient database — Route: INTRAMUSCULAR; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 13 mg
- US: inactive ingredient database — Route: INTRAMUSCULAR; Dosage form: INJECTION, SUSPENSION, EXTENDED RELEASE; Maximum daily exposure: 30 mg
- US: inactive ingredient database — Route: INTRASYNOVIAL; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 13 mg
- US: inactive ingredient database — Route: INTRAVASCULAR; Dosage form: INJECTION; Potency: 0.15 mg
- US: inactive ingredient database — Route: INTRAVENOUS; Dosage form: INJECTION; Maximum daily exposure: 120 mg
- US: inactive ingredient database — Route: INTRAVENOUS; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: 13.61 mg
- US: inactive ingredient database — Route: INTRAVENOUS; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: 15.55 mg
- US: inactive ingredient database — Route: INTRAVENOUS; Dosage form: INJECTION, SOLUTION; Maximum daily exposure: 27 mg
- US: inactive ingredient database — Route: INTRAVESICAL; Dosage form: SOLUTION; Potency: 0.12 mg
- US: inactive ingredient database — Route: INTRAVITREAL; Dosage form: INJECTION; Potency: 0.86 %w/v
- US: inactive ingredient database — Route: INTRAVITREAL; Dosage form: INJECTION, SUSPENSION; Potency: 0.04 %w/v
- US: inactive ingredient database — Route: OPHTHALMIC; Dosage form: SOLUTION; Maximum daily exposure: 4 mg
- US: inactive ingredient database — Route: OPHTHALMIC; Dosage form: SOLUTION/ DROPS; Maximum daily exposure: 8 mg
- US: inactive ingredient database — Route: OPHTHALMIC; Dosage form: SUSPENSION; Potency: 0.04 %w/w
- US: inactive ingredient database — Route: ORAL; Dosage form: CAPSULE; Potency: 600 mg
- US: inactive ingredient database — Route: ORAL; Dosage form: INJECTION; Potency: 10.06 mg
- US: inactive ingredient database — Route: ORAL; Dosage form: SOLUTION; Maximum daily exposure: 1500 mg
- US: inactive ingredient database — Route: ORAL; Dosage form: SUSPENSION; Maximum daily exposure: 104 mg
- US: inactive ingredient database — Route: ORAL; Dosage form: SYRUP; Potency: 20.6 mg/5ml
- US: inactive ingredient database — Route: ORAL; Dosage form: TABLET; Potency: 31.72 mg
- US: inactive ingredient database — Route: ORAL; Dosage form: TABLET, DELAYED RELEASE; Potency: 35 mg
- US: inactive ingredient database — Route: ORAL; Dosage form: TABLET, FILM COATED; Potency: 0.11 mg
- US: inactive ingredient database — Route: SOFT TISSUE; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 13 mg
- US: inactive ingredient database — Route: SUBCUTANEOUS; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Maximum daily exposure: 2 mg
- US: inactive ingredient database — Route: SUBCUTANEOUS; Dosage form: SUSPENSION; Potency: 0.07 %w/v
- US: inactive ingredient database — Route: TOPICAL; Dosage form: CREAM; Maximum daily exposure: 10 mg
- US: inactive ingredient database — Route: TOPICAL; Dosage form: LOTION; Maximum daily exposure: 8 mg
- US: inactive ingredient database — Route: TOPICAL; Dosage form: LOTION, AUGMENTED; Maximum daily exposure: 10 mg
- US: inactive ingredient database — Route: TOPICAL; Dosage form: SOLUTION; Potency: 0.46 %w/v
- US: marketed drug occurrence — FDA NDC lists this ingredient in 48 active drug products and 49 total products.
- US: listed in openFDA substance — openFDA substance registry classifies this ingredient as chemical.

_Assessed by Greenveil._